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Widespread elevations in brain urea have, in recent years, been reported in certain
types of age-related dementia, notably Alzheimer’s disease (AD) and Huntington’s
disease (HD). Urea increases in these diseases are substantive, and approximate in
magnitude to levels present in uraemic encephalopathy. In AD and HD, elevated urea
levels are widespread, and not only in regions heavily affected by neurodegeneration.
However, measurements of brain urea have not hitherto been reported in Parkinson’s
disease dementia (PDD), a condition which shares neuropathological and symptomatic
overlap with both AD and HD. Here we report measurements of tissue urea from
nine neuropathologically confirmed regions of the brain in PDD and post-mortem
delay (PMD)-matched controls, in regions including the cerebellum, motor cortex
(MCX), sensory cortex, hippocampus (HP), substantia nigra (SN), middle temporal
gyrus (MTG), medulla oblongata (MED), cingulate gyrus, and pons, by applying
ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-
MS/MS). Urea concentrations were found to be substantively elevated in all nine
regions, with average increases of 3–4-fold. Urea concentrations were remarkably
consistent across regions in both cases and controls, with no clear distinction between
regions heavily affected or less severely affected by neuronal loss in PDD. These urea
elevations mirror those found in uraemic encephalopathy, where equivalent levels are
generally considered to be pathogenic, and those previously reported in AD and HD.
Increased urea is a widespread metabolic perturbation in brain metabolism common
to PDD, AD, and HD, at levels equal to those seen in uremic encephalopathy. This
presents a novel pathogenic mechanism in PDD, which is shared with two other
neurodegenerative diseases.
Keywords: Parkinson’s disease dementia (PDD), Huntington’s disease (HD), Alzheimer’s disease (AD), urea-
analysis, metabolomics (OMICS), mass spectrometry-LC-MS/MS
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INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative condition after Alzheimer’s disease (AD;
Erkkinen et al., 2018). PD is characterised mainly by motor
dysfunction including bradykinesia, resting tremor, and rigidity.
Up to 80% of patients with PD develop cognitive dysfunction
during the course of their disease, usually within 20 years
from the diagnosis, designated as Parkinson’s disease dementia
(PDD; Hely et al., 2008). Neuropathologically, PD and PDD are
characterised by extensive loss of dopaminergic neurons in the
substantia nigra (SN), and accumulation and progressive spread
of misfolded α-synuclein with formation of Lewy bodies and
Lewy neuropil threads. Deposition of α-synuclein is thought to
begin in the olfactory bulbs and lower brainstem and progress to
the midbrain and eventually to the neocortex (Braak et al., 2003;
Jellinger, 2019). The severity of α-synuclein deposition in the
post-mortem brain is assessed using the Braak staging system.
A conclusive clinical diagnosis of PD/PDD can be challenging
due to the heterogeneity of the condition, presence of
comorbidities and overlap with other forms of movement
disorders and dementia (Irwin et al., 2013; Walker et al., 2019).
The hypothesis that different forms of dementia represent a
spectrum with common pathogenetic mechanisms has been
suggested (Perl et al., 1998; Jellinger and Korczyn, 2018).
Studies that search for perturbations in different areas of the
brain across different neurodegenerative conditions represent an
approach to unveil potential common pathogenetic mechanisms.
Previous metabolomics studies have investigated AD and HD and
demonstrated widespread increases in brain-tissue urea in both
these conditions despite their different clinical phenotypes and
genetic alterations (Patassini et al., 2015, 2016; Xu et al., 2016;
Handley et al., 2017).
Peripheral blood levels of urea have been reported in PD
patients with discordant results including increase in plasma
(Glaab et al., 2019), no change in serum (Hatano et al., 2016),
decreases in the CSF (Trezzi et al., 2017), and decrease in whole
blood concentrations (Troisi et al., 2019). Additionally, none
of these studies of peripheral urea distinguished between PD
with or without dementia. Conclusions on cerebral tissue levels
of this metabolite cannot be inferred from these studies but to
our knowledge, brain-tissue urea levels have not previously been
reported in PDD.
MATERIALS AND METHODS
Obtaining Tissue for Urea Quantification
For this study, tissues from nine brain regions from nine
cases with definitely diagnosed PDD and nine controls were
obtained from the University of Miami Brain Endowment Bank,
Miami, FL, United States (part of the National Institute of
Health NeuroBioBank network). Tissues were dissected from
the following human-brain regions: middle temporal gyrus
(MTG); motor cortex (MCX); primary visual cortex (PVC);
hippocampus (HP); anterior cingulate gyrus (CG); cerebellum,
at the level of the dentate nucleus (CB); SN; pons; and
medulla oblongata (MED). All available patient metadata for
cases and controls were obtained and are herein presented in
Supplementary Tables A2, 3.
Diagnosis and Severity of Parkinson’s
Disease Dementia Cases
Cases and controls were diagnosed by the referring
neuropathologists of the Miami Brain Endowment Bank.
All cases were diagnosed to be of the alpha-synucleinopathy
neocortical type, consistent with the clinical phenotype of
PDD. Controls did not show any features of neurodegeneration
or vascular pathology. The brains were assessed using either
Braak staging (Braak et al., 2003) and/or McKeith’s staging
criteria for Lewy body dementias (McKeith et al., 2005; see
Supplementary Material A).
Tissue Dissection
Brain samples were cut into sections of 50 mg (±5 mg) for urea
quantification using a metal-free ceramic scalpel. Samples were
stored in “Safe-Lok” microfuge Eppendorf tubes (Eppendorf AG;
Hamburg, Germany) and stored at −80◦C prior to extraction.
Urea Quantification
Urea was quantified in brain sample by UHPLC-MS/MS. Brain
samples were extracted in 50:50 (v/v) methanol:chloroform
containing labelled urea internal standard [Urea-15N2
98 atom% 15N, 99% (CP), 316830 Sigma-Aldrich, MO,
United States]. Extraction blanks containing only the
methanol:chloroform:internal standard solvent were prepared.
Samples were lysed in a TissueLyser batch bead homogeniser
(Qiagen, Manchester, United Kingdom). LC-MS grade water was
then added to samples before separation of polar and non-polar
phases by centrifugation at 2,400 × g for 15 min. The polar
methanol phase was transferred to a fresh tube before being
dried overnight in a Speedvac centrifugal concentrator (Savant
Speedvac, Thermo Scientific, United Kingdom).
Once dried, 0.1% formic acid was added to samples. The
resulting solution was transferred to 300-µl autosampler vials,
with two blanks containing only 0.1% (v/v) formic acid also
prepared. Standard solutions containing a labelled urea internal
standard and corresponding unlabelled urea external standards
(urea analytical standard, 56180 Supelco, PA, United States) were
prepared, containing concentrations of 0–5,000 µM unlabelled
urea in 0.1% v/v formic acid. Three QC samples were also
prepared containing 10 µm labelled urea and 20, 200, and
2,000 µM unlabelled urea in 0.1% v/v formic acid.
Urea quantification was performed on a TSQ Vantage triple
quadrupole mass spectrometer coupled with an Accela UHPLC
system (Thermo Fisher Scientific, MA, United States). Separation
was carried out on a Hypersil Gold AQ column with a diameter of
2.1 mm, length of 100 mm, and particle size of 1.9 µm (Thermo
Fisher Scientific) maintained at 25◦C with a 0.5 µm pre-column
filter (Thermo Fisher Scientific). Gradient elution was performed
using 0.1% formic acid in water (A) and 0.1% formic acid in
acetonitrile (B) at 300 µl/min. Urea and labelled urea internal
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Ultra-high-performance liquid chromatography-tandem mass
spectrometry data were analysed using LCQuan software
(Thermo Fisher Scientific, MA, United States). Chromatographic
peaks were identified based on expected retention time (RT), and
compared against labelled urea internal standard peak RTs for
each individual QC/standard/sample. Each peak was manually
checked for correct identification.
Quantification of urea in samples was performed using the
ratio of urea peak area to internal standard peak area and
comparison to the standard curve. These concentrations were
corrected for sample wet-weight and analysed in GraphPad Prism
v8.1.2. (Prism; La Jolla, CA, United States). A non-parametric
Mann-Whitney-U test was used to determine the significance of
case-control differences due to the relatively small sample sizes.
The minimum sample size required to confidently determine
case-control differences at a significance level of p < 0.05 and
p < 0.01 was calculated using the sample size calculator from SPH
Analytics, Alpharetta, United States.1
RESULTS AND DISCUSSION
Cohort Characterisation
Metadata were obtained for all cases and controls, including
sex, age, race, ethnicity, post-mortem delay (PMD), brain
weight, comorbidities, and cause of death (see Supplementary
Material A for individual data). There were no significant case-
control differences in sex, age at death, PMD or brain weight
(Supplementary Table A1). All samples had a PMD of 26 h or
less, with an average of 19.8 h in controls and 14.6 h in cases.
Due to a lack of available SN tissue for two of the cohort
samples, two alternate SN samples were obtained from different
donors. These samples were age- and sex-matched, but the cases
had a lower PMD than controls (∼6 h, p = 0.03; Supplementary
Table A1). The impact of this is discussed in the section on brain
tissue urea findings below.
Brain Tissue Urea Findings in
Parkinson’s Disease Dementia
Urea levels were increased in PDD cases compared to controls
in every region analysed (Table 1 and Figure 1). There was an
average 5.5-fold increase in tissue-urea concentrations in the CG
of cases compared with controls, and an average ∼3.5- to 4.5-fold
increase in cases in every other region.
Inter-regional concentrations of urea were highly consistent in
both controls and cases, with no significant differences between
any two regions. Control tissue-urea concentrations averaged
∼9.4 mmol/kg and case concentrations 40.0 mmol/kg, showing
a substantial, ∼4-fold increase in case-control urea levels across
the brain overall.
1https://www.sphanalytics.com/sample-size-calculator-using-average-values/








CB 9.6 (2.7–16.4) 35.2
(15.4–55.0)
3.7 0.003
MCX 9.2 (2.5–16.0) 37.7
(15.7–59.7)
4.1 0.002
PVC 8.1 (2.3–13.9) 34.9
(14.6–55.2)
4.3 0.001
HP 9.0 (2.6–15.4) 37.6
(10.7–64.4)
4.2 0.004
SN 11.6 (3.4–19.9) 45.8
(17.3–74.2)
3.9 0.006
MTG 11.0 (2.3–19.6) 46.9
(17.9–76.0)
4.3 0.002
MED 8.5 (2.3–14.7) 38.9
(14.9–62.9)
4.6 0.002
CG 8.8 (3.0–14.6) 48.4
(17.6–79.1)
5.5 0.0008
PONS 8.8 (2.2–15.5) 34.2
(15.4–53.0)
3.9 0.003
Mean tissue-urea concentrations ± 95% confidence intervals expressed in
mmol/kg. Significance of case-control differences was determined using the Mann-
Whitney-U test wherein P < 0.05 has been considered significant. Fold-changes
are cases compared to controls.
Bolded values show significant case-control differences.
Neither of the substituted SN samples showed significant
differences in urea concentrations compared with other
cases in the cohort (see Supplementary Material B for
individual values). Case-control differences in SN-urea levels
remained significant with exclusion of substituted SN controls
C10 and C11.
As sample sizes in this study were small, a study measuring the
statistical power of the urea values was conducted. This found
a statistical power of over 80% in the CB, MCX, PVC, MED,
CG, and PONS, over 70% in the SN and MTG, and a lower
value of 68.7% in the HP for p < 0.05. This indicates good
statistical power in most regions, but highlights the necessity
of larger sample sizes for more robust measurements. The
same test showed a required sample size of 3 for confident
identification of case-control differences at p < 0.05 for all
regions except the HP, which showed a required sample
size of 4.
Comparisons With Brain Urea
Concentrations in Alzheimer’s Disease
and in Huntington’s Disease
Our group has previously reported severe and regionally
widespread increases in brain-tissue urea concentrations in cases
with AD dementia (Xu et al., 2016), and with HD dementia
(Patassini et al., 2015, 2016). In these studies, AD and HD brain-
tissue urea values were reported from multiple regions compared
between cases and matched controls [Table 2 and Figure 2; refs
(Patassini et al., 2015, 2016; Xu et al., 2016)].
Although there are some differences in the methodologies
used in the two former studies compared with the current one
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FIGURE 1 | Urea concentrations in PDD cases and matched controls. Mean tissue urea concentrations ± 95% confidence intervals expressed in mmol/kg.
Case-control differences were determined by applying the Mann-Whitney-U test. **p < 0.01 and ***p < 0.001. C, control; PDD, Parkinson’s disease dementia case.
(such as previous use of gas chromatography-mass spectrometry,
and some differences in the regions studied; Figure 2), case-
control tissue-urea fold-changes can be compared between PDD,
HD, and AD (Table 2) across several brain regions.
Cases and controls in the HD study were slightly younger
than those in the current PDD cohort, at an average of around
3 years for controls and 8 years for cases (Patassini et al.,
2015, 2016). Moreover, PMD was significantly lower than in the
current PDD cohort, at an average of ∼11 h in both cases and
controls. Cause of death in the HD cohort was most commonly
bronchopneumonia in cases and heart failure in controls, but data
on comorbidities and other vascular pathology were unavailable.











CB 3.7 4.9 3.6
MCX 4.1 5.0 3.4
PVC 4.3 4.9 3.4
HP 4.2 6.5 3.6
SN 3.9 – 3.5
MTG 4.3 4.7 3.4
MED 4.6 – –
CG 5.5 5.3 3.5
PONS 3.9 – –
PUT – – 3.7
GP – – 3.6
MFG – – 3.0
ENT – 5.6 2.8
Overall 4.3 (3.9–4.6) 5.3 (4.8–5.8) 3.5 (3.2–3.6)
Comparisons of case-control fold-changes in human brain urea levels between
PDD, AD, and HD. Case-control differences were significant for every region
in every disease. Overall shows mean overall fold-change with ± 95%
confidence intervals.
Brain tissue-urea concentrations showed a similar average fold-
increase to that measured in PDD of 3.5 in HD cases compared
to controls (Table 2 and Figure 2). As in PDD, the increase
was observed in the SN, CB, HP, MTG, CG, SCX, and MCX, as
well as in other regions not included in the current PDD study,
such as the putamen, globus pallidus, middle frontal gyrus, and
entorhinal cortex.
The AD cases whose brain-tissue urea levels we measured were
similar in age to the current PDD cohort, with an average of
∼70 years in both cases and controls (Xu et al., 2016). PMD was
also significantly shorter in this cohort, at an average of 9 h in
controls and 7 h in cases. Causes of death were varied in both
cases and controls, most commonly being due to heart or lung
complications. Comorbidity and vascular pathology metadata
were not available. Although absolute tissue-urea concentrations
cannot be directly compared to the previous studies in AD brains,
there was a higher average case-control fold-change in AD than
that observed here in PDD, the average being ∼5.3-fold, but with
increases as high as 6.5-fold in the HP (Xu et al., 2016; Table 2).
Tissue-urea elevations in this AD cohort were observed in the HP,
MTG, SCX, MCX, CG, and CB, as well as in the entorhinal cortex
(which was not included in the current study). The AD cohort
was similar in age to the current PDD cohort.
Comparisons of case-control fold-changes in human brain
urea levels between PDD, AD, and HD. Case-control differences
were significant for every region in every disease. Overall shows
mean overall fold-change with ± 95% confidence intervals.
Additional studies have also confirmed urea increases in AD
(Gueli and Taibi, 2013) and HD (Handley et al., 2017) brains,
although one study reported decreases in the HD striatum and
no change in the HD frontal lobe (Graham et al., 2016). Such
discrepancies may be contributed to by differences in methods
used or between cohorts, such as differences in PMD. However,
we have previously observed that PMD does not affect urea levels
for up to 72 h in rat brains (Scholefield et al., 2020), although this
may not necessarily also be the case in human brains.
Together, the observations in PDD, AD, and HD suggest a
shared pathogenic mechanism in these three diseases, despite
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FIGURE 2 | Regional Distribution of Measured Tissue Urea Increases in the PDD, AD, and HD Brain. Areas shaded in red denote significant increases in urea
compared to intra-cohort controls. Areas shaded in grey were not investigated in the illustrated studies.
apparent differences in causative processes and symptomology.
There appear to be regional differences between diseases with
respect to tissue-urea elevations. For example, AD showed
the highest increases in the severely affected HP (6.5-fold),
whereas in HD the putamen showed slightly higher-than-
average elevations (3.7-fold). These regional differences may
contribute to differences in severity and pathogenesis in the
different conditions. Interestingly, the CG showed the highest
urea increase in PDD (5.5-fold); the anterior CG is involved
in emotive states and emotionally-coded memories. All other
studied regions of the PDD brain showed urea increments of
around 3.5- to 4.5-fold. However, there were no statistically
significant differences between different PDD-control regions
or between different PDD-case regions. Greater power (by
increasing the sample size), would probably be required to
determine whether the fold-elevation observed in the CG is
significantly greater than that of other regions of the PDD
brain. If so, it is possible that the prominence of both motor
and cognitive dysfunction in PDD correlates with similar tissue
urea elevations in areas involved in both cognition and motor
control processes–a future investigation into regional tissue urea
dysregulation in PD brains without dementia could help elucidate
this and would probably be a logical next step.
Urea’s main metabolic function is to provide a route for the
excretion of nitrogen-containing moieties derived from toxic
nitrogen-containing compounds. In the urea cycle, ammonia is
converted into urea, which is then excreted from the body via
the urine. Urea is mainly produced in the liver and is carried
to other parts of the body via the blood stream. However, it
is slow to cross the blood-brain barrier (BBB; Sterns et al.,
2015), leading to the question as to whether cerebral urea does
in fact enter the brain through the BBB, or whether it is also
produced in the brain. There is little evidence for the presence
of intracerebral urea cycle activity, although there have been
limited observations of partial activity in some studies. For
example, some studies have identified increased expression of
arginase I (ARG1) mRNA in AD brains and the brains of the
APPsw mouse model of AD (Colton et al., 2006), as well as
increased arginase activity in human AD brains–accompanied by
concurrent decreases in ornithine (Liu et al., 2014). Arginase is
the final enzyme of the urea cycle, responsible for conversion of
arginine to urea–as such, increased arginase activity could result
in increased urea levels. A proteomics study conducted by our
own lab on several regions of the AD brain observed arginase II
in the CB, but did not observe any case–control changes in the
enzyme; ARGI was not identified in any region (Xu et al., 2019).
Triple transgenic AD mouse models have also exhibited reduced
amyloid-β deposits, microgliosis, and spatial memory deficits
with administration of arginase inhibitor L-norvaline (Polis et al.,
2018). Administration of an arginase-1 inhibitor has also been
found to be protective against midbrain dopaminergic neuronal
loss induced in rat brain slice cultures by arginase-1 promoter
macelignan (Kiyofuji et al., 2015). A network analysis has also
found arginine pathways be enriched in both PD and AD, as well
as in amyotrophic lateral sclerosis (Kori et al., 2016), possibly
resulting in downstream upregulation of nitric oxide synthesis,
leading to hypoxia, which has been implicated in both PD and
AD (Virarkar et al., 2013). Together, these results suggest a role
for arginase in AD and PD pathology.
However, arginase is only one component of the urea cycle
and is not sufficient for complete urea cycle activity; another
urea cycle component–ornithine transcarbamylase (OTC)–the
enzyme responsible for the conversion of ornithine to citrulline
in the urea cycle, was initially reported to be expressed only in
AD brains (Bensemain et al., 2009), but has also been observed in
healthy control brains in limited amounts (Bernstein et al., 2015,
2017). However, studies attempting to investigate the levels of
other urea cycle enzymes in HD sheep model brains for example
were unable to identify either OTC or carbamoyl phosphate
synthetase I in the striatum (Handley et al., 2017). Additionally,
a more recent large-scale proteomic study of six regions of
human AD and control brains was unable to identify the presence
of either of these urea cycle enzymes at the protein level (Xu
et al., 2019). As such, it is possible that upregulation of OTC in
AD brains leads to urea cycle activity in the brain that would
otherwise not be present, characterised by increased urea and
arginase activity and decreased ornithine, but the lack of other
urea cycle components makes definite conclusions difficult to
draw at this stage. It is not yet known whether increases in OTC
are also present in the PDD brain.
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Some other urea cycle components such as adenosine
(McFarland et al., 2013; Xu et al., 2016; Alonso-Andres et al.,
2018), citrulline (Liu et al., 2014), and ornithine (Gueli and
Taibi, 2013; Liu et al., 2014) have been reported in the AD
brain, as well as the HD brain (Graham et al., 2016; Patassini
et al., 2016)—however, as these metabolites are also involved in
other metabolic pathways, this does not necessarily indicate urea
cycle activity. For example, adenosine is a core component of
several widespread co-enzymes such as adenosine triphosphate
(ATP), diphosphate (ADP), and monophosphate (AMP) which
are crucial to a wide variety of metabolic pathways including
the ETC (Nolfi-Donegan et al., 2020), TCA cycle (Madeira,
2018), and purine metabolism (Ichida et al., 2009). As such, it
seems likely that cerebral urea may be formed by an alternative
process, either by itself or in addition to potential urea cycle
activity in the brain.
Several urea cycle intermediates have also been reported to
be dysregulated in PD serum, plasma, and CSF. Arginine has
been reported by some investigations to be decreased in PD
serum (Mally et al., 1997) and CSF (Molina et al., 1997), although
other reports have observed no changes in either the serum
(Hatano et al., 2016), CSF (Mally et al., 1997; Engelborghs et al.,
2003), or plasma (Molina et al., 1997). There is one report of
increased citrulline in PD serum (Han et al., 2017), although
another investigation reported no change (Hatano et al., 2016),
and further reports indicated no change in the CSF (Molina
et al., 1997; Engelborghs et al., 2003) or plasma (Iwasaki et al.,
1992; Molina et al., 1997). Increases in PD serum ornithine have
been reported (Hatano et al., 2016), with varying reports in the
CSF of decrease (Molina et al., 1997), increase (Wuolikainen
et al., 2016), or no change (Engelborghs et al., 2003). Moreover,
no changes have been reported by several groups in studies of
plasma ornithine in PD (Iwasaki et al., 1992; Molina et al., 1997;
Wuolikainen et al., 2016). None of these urea cycle components
have been reported on in the PD/PDD brain itself, and the
investigations of peripheral levels in the plasma, CSF, and serum
have reported inconsistent results. As such, this entire pathway,
and the possibility of partial or whole urea cycle activity in the
brain, presents a novel area for future investigation of PDD.
Protein dysregulation and neuronal death may lead to
greater protein breakdown, and so to increased urea production.
Disruptions to the BBB, as observed in PDD (Sweeney et al.,
2018), may result in defective urea clearance from the brain
or increased entry of urea from the bloodstream via urea
transporters. Urea transporters are responsible for regulating
movement of urea by facilitating urea diffusion, and are expressed
in astrocytes and the BBB as well as outside the brain. Urea
transporter B has been shown to be upregulated in the HD CB,
which may reflect attempts to clear elevated urea levels in the HD
brain (Handley et al., 2017). Urea transporters have not yet been
investigated in PD/PDD, but may show similar perturbations to
those reported in HD.
Urea accumulation caused by kidney failure is known to
be toxic to the brain, leading to a condition called uraemic
encephalopathy (Seifter and Samuels, 2011). High urea levels
lead to synaptic loss and inhibition of long-term potentiation
via carbamylation of mTOR in a chronic kidney disease mouse
model (Wang H. et al., 2019). Carbamylation is a post-
translational modification involving the addition of isocyanate,
usually derived from urea, to protein-bound amino-acid residues,
causing alterations in the structure and function of the affected
proteins. Increased carbamylation has been observed in aging
humans (Gorisse et al., 2016), and as a result of chronic kidney
disease (Long et al., 2018) as well as in AD with cerebrovascular
disease (Gallart-Palau et al., 2017). It has been shown that tau,
which is aggregated in AD and also to a lesser degree in PDD, can
be carbamylated, resulting in increased amyloid formation and
tau accumulation (Guru KrishnaKumar et al., 2018). Whether
α-synuclein may also be carbamylated is unknown, but it
does contain several potentially susceptible amino-acid residues,
which might serve as target sites for carbamylation.
High urea levels in chronic kidney disease and renal
failure have also been linked to increased oxidative stress
(Vaziri, 2004). Oxidative stress is a well-recognised feature
of PD, AD, and HD (Yan et al., 2013; Graham et al., 2016)
and is linked to other pathogenic mechanisms including
mitochondrial dysfunction and proteinopathy (Ganguly et al.,
2017), dysregulated glucose metabolism (Butterfield and
Halliwell, 2019), insulin resistance and inflammation (Verdile
et al., 2015), and α-synuclein accumulation, oligomerisation,
and phosphorylation (Scudamore and Ciossek, 2018; Wang R.
et al., 2019). As such, it is possible that elevated urea levels
in PDD could contribute to one or more of these known
pathogenic mechanisms.
Weaknesses of the current study include small sample sizes
of a maximum of 9 v 9 in all three diseases. However, analyses
of statistical power show good values, at >80% in most PDD
brain regions. Non-parametric tests were also employed due to
the small sample size in order to avoid type I errors during
statistical analysis. Despite this, larger sample sizes would lead to
more robust findings. There are also some regions of the PDD
brain that may have been of interest for comparison with other
dementias, such as the putamen and caudate nucleus, which are
both heavily affected in both PDD and HD. However, this study
was limited by the number of available regions for the same
donors (which allow for more direct intraregional comparisons
of urea concentrations), and also due to our aim of including
not only heavily affected regions, but also moderately affected
and relatively spared regions. As such, future investigations
should try to include such areas, which to our knowledge
have yet to be investigated in terms of urea concentrations
in PDD. An additional weakness in this study is a lack of
additional metadata, such as the duration of Parkinsonism and
dementia symptoms in PDD cases, or data on renal functions
in donors. Unfortunately, this data was not available for the
tissues obtained in this study; although no cases or controls
were reported as having renal issues involved in their cause
of death, it is unknown whether they had any kidney-related
comorbidities before death.
The strengths of this study are the use of highly precise
quantitative UHPLC-MS/MS methods, performed in such a
way as to make the measured values directly comparable
to brain tissues from previous analyses of other dementia
diseases. The cohort used for this study was also very
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well-matched, with only a small difference in PMD between
SN cases and controls. Data was also obtained on donor
cause of death and neuropathology–as provided by referring
neuropathologists at the brain bank–which is not always available
in studies such as these. Statistical tests of study power showed
values of >80% in most regions, suggesting good statistical power
at p > 0.05. Although larger sample sizes are required for further
studies, this suggests that a good amount of confidence can be had
in the results reported here.
CONCLUSION
In conclusion, this investigation shows widespread urea
accumulation throughout the PDD brain, similar to that
previously observed in AD and HD, with concentrations
comparable to those seen in uremic encephalopathy. This
suggests a novel shared pathogenic insult across multiple
neurodegenerative conditions and may indicate a common
mechanism in the development of cognitive impairment.
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